CN113801140A - Isoleucinine analogs, and preparation method and application of isoleucinine analogs from levofloxacin to isoleucinine analogs - Google Patents

Isoleucinine analogs, and preparation method and application of isoleucinine analogs from levofloxacin to isoleucinine analogs Download PDF

Info

Publication number
CN113801140A
CN113801140A CN202111246352.1A CN202111246352A CN113801140A CN 113801140 A CN113801140 A CN 113801140A CN 202111246352 A CN202111246352 A CN 202111246352A CN 113801140 A CN113801140 A CN 113801140A
Authority
CN
China
Prior art keywords
analogue
levofloxacin
indoloquinoline
isoleucinine
isoalbutine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202111246352.1A
Other languages
Chinese (zh)
Other versions
CN113801140B (en
Inventor
黄帅
路长远
楚红英
许俊丽
晋秋芝
张堋梁
胡国强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan University
Yellow River Conservancy Technical Institute
Original Assignee
Henan University
Yellow River Conservancy Technical Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan University, Yellow River Conservancy Technical Institute filed Critical Henan University
Priority to CN202111246352.1A priority Critical patent/CN113801140B/en
Publication of CN113801140A publication Critical patent/CN113801140A/en
Application granted granted Critical
Publication of CN113801140B publication Critical patent/CN113801140B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The invention provides an isoalbutine analogue, a preparation method and application of isoalbutine analogue from levofloxacin to isoalbutine analogue, which are used for solving the technical problem of designing an indoloquinoline antituberculosis drug with a novel structure by taking albutine alkaloid as a precursor and adopting an atom economic strategy. The invention selects levofloxacin to prepare the isoalbuterol analogue, realizes effective chemical construction from a fluoroquinolone structure to an indoloquinoline skeleton, expands a new approach of structural modification of isoalbuterol, and achieves the complementary of the advantageous structures of the fluoroquinolone medicament and the natural indoloquinoline alkaloid. The in vitro antituberculosis activity test result shows that the compound has better growth inhibition activity on a tested tuberculosis strain, the activity of part of the compound is equivalent to that of a control isoniazid, and the compound has the advantages of drug resistance and lower cytotoxicity, and can be further developed and prepared as an antituberculosis drug with a brand new structure.

Description

Isoleucinine analogs, and preparation method and application of isoleucinine analogs from levofloxacin to isoleucinine analogs
Technical Field
The invention relates to the technical field of medicinal chemistry related to organic synthesis and new medicament research and development, in particular to an isoalbutine analogue, and also relates to a preparation method of the isoalbutine analogue from levofloxacin to isoalbutine analogue, and application of the isoalbutine analogue in preparation of antituberculosis medicaments.
Background
Tuberculosis is a chronic infectious disease with high morbidity caused by tubercle bacillus, and is an urgent public health and social problem facing the world due to the lack of effective therapeutic drugs. Meanwhile, the tubercle bacillus is easy to generate drug resistance to the existing drugs, especially the generation of multi-drug resistance, and provides new challenges for developing anti-tuberculosis drugs, so that no novel compound is available for treating tuberculosis for more than half a century since the rifampicin anti-tuberculosis drugs are found. Therefore, the development of antituberculosis drugs is a complicated intellectual innovation engineering with high time consumption and high investment, and is receiving attention. Wherein, the effective components of natural medicines are used as leads, and the structure of the natural medicines is optimized and modified, which is the most economic and effective strategy for finding new medicines. In the research and development of various natural active ingredients, the cryptolepine alkaloids with indoloquinoline as the structural characteristic skeleton, such as cryptolepine (A), isocryptolepine (B), neocryptolepine (C) and the like,
Figure BDA0003321131400000011
the structure is unique, and the anti-plasmodium falciparum and anti-tumor biological activities are better, so that the research interest is aroused, but the reports on the anti-tuberculosis activity are few. However, the source of the solanum lyratum alkaloid is difficult, and the bioavailability is low due to the poor water solubility, so that the clinical application is limited. Therefore, how to design the indoloquinoline antituberculosis drugs with novel structures by using the solanum glaucescens alkaloids as a precursor and an atom economic strategy is very important. On one hand, the fluoroquinolone-based medicine is not only a clinically important antibacterial medicine, but also a clinical second-line antituberculosis medicine, for example, the advantageous structures of the solanum lyratum alkaloid and the fluoroquinolone are combined to play the advantages of respective pharmacophores, and a novel indoloquinoline antituberculosis medicine is possibly designed and found; on the other hand, by introducing effective substituent groups in fluoroquinolone medicine molecules, the pharmacodynamics and pharmacokinetic properties of the fluoroquinolone medicine molecules are further improved so as to overcome the defects of the conventional alkaloid and promote the development of the pharmacy of novel indoloquinoline antituberculosis medicines.
Disclosure of Invention
The invention provides an isoalbuterol analogue, and also relates to a preparation method of the isoalbuterol analogue from levofloxacin to isoalbuterol analogue, and application of the isoalbuterol analogue in preparation of antituberculosis drugs, aiming at solving the technical problem of designing novel-structure indoloquinoline antituberculosis drugs by using albuterol alkaloids as a precursor and adopting an atom economic strategy. The invention uses commercially available fluoroquinolone drug levofloxacin (II) as raw material, and the raw material is reduced and deacidified to quinolinone (S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazine-1-yl) -2, 3-dihydro-quinoline-4 (1H) -ketone, III), and then the quinolinone and phenylhydrazine are synthesized by Fisher indole to successfully construct an isoalbuterol analogue; isoalbuterone (B) in the albuterone alkaloids is selected as a precursor, indolo [3,2-c ] quinoline is used as a dominant skeleton, hydrophilic basic piperazinyl in a fluoroquinolone medicine structure is introduced to increase water solubility and improve bioavailability, and introduction of fluorine atoms can increase permeability of medicine molecules to improve bioactivity.
In order to achieve the purpose, the technical scheme of the invention is realized as follows:
an isoalburnine analogue has a chemical structural general formula shown in formula I:
Figure BDA0003321131400000021
the substituent R in the formula I can be independently hydrogen atom-H, methoxy-OCH3methyl-CH3Fluorine atom-F, chlorine atom-Cl or xanthylamino-SO2NH2。
Preferably, the chemical structural formula of the isoalburnine analogue is:
Figure BDA0003321131400000031
Figure BDA0003321131400000041
a preparation method of an isobaicamine analogue from levofloxacin comprises the following steps:
s1, carrying out reduction decarboxylation reaction on levofloxacin shown in a formula II serving as a raw material and potassium borohydride to obtain 2, 3-dihydroquinolin-4-one shown in a formula III;
Figure BDA0003321131400000042
s2, preparing the cryptolepine alkaloid with the mother nucleus structure characteristic of the indoloquinoline by the Fischer indole synthesis method by using the 2, 3-dihydroquinoline-4-ketone and the phenylhydrazine obtained in the step S1;
Figure BDA0003321131400000051
s3, carrying out post-treatment on the Sinomenine alkaloid with the mother nucleus structure characteristic of the indoloquinoline obtained in the step S2 to obtain the isoSinomenine analogue as the claim 1 or 2.
Preferably, S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -2, 3-dihydro-quinolin-4 (1H) -one, III, shown in formula III, is prepared from commercially available levofloxacin, shown in formula II, by reductive decarboxylation with a commercially available analytical pure chemical reagent, sodium borohydride, by a similar procedure to that described in the references Kondo H, Sakamoto F, et al, study on precursors.7. Synthesis and antibiotic activity of 3-formalquinolone derivatives, J Med Chem,1988,31(1): 221-.
Figure BDA0003321131400000052
As a further improvement, the potassium borohydride which is cheap, difficult to absorb moisture and mild in reaction is used for replacing sodium borohydride in the literature.
Step S1 specifically includes the following steps:
y1, mixing levofloxacin and a solvent to prepare a suspension, slowly adding potassium borohydride into the suspension in a fractional manner under stirring at normal temperature, heating the mixed reactant in a water bath, and stirring and refluxing to react until the levofloxacin disappears to obtain a mixed solution;
y2, placing the mixed solution obtained in the step Y1 to room temperature, and evaporating the solvent in the mixed solution by using an evaporator to obtain a residue;
y3, adding the remainder obtained in the step Y2 into deionized water, mixing, adjusting the pH to be approximately equal to 2 by using concentrated hydrochloric acid, adding activated carbon for decoloring, adjusting the pH to be approximately equal to 10 by using sodium hydroxide with the mass concentration of 30%, and standing to separate out a solid;
y4, and recrystallizing the solid precipitated in the step Y3 by hot water and n-hexane in sequence to obtain the 2, 3-dihydroquinolin-4-one.
Preferably, step S2 specifically includes the following steps:
t1, dissolving the 2, 3-dihydroquinolin-4-one obtained in the step S1 in absolute ethyl alcohol, adding phenylhydrazines, and stirring at normal temperature until the 2, 3-dihydroquinolin-4-one disappears to obtain a mixed solution;
t2, adding a cyclization catalyst into the mixed solution obtained in the step T1 dropwise, carrying out heating reflux reaction, standing to room temperature, and filtering to collect the generated albophylline alkaloid with the mother nucleus structure characteristics of indoloquinoline.
Preferably, step S3 specifically includes the following steps:
z1, dissolving the cryptolepine alkaloid with the mother nucleus structure characteristics of the indoloquinoline obtained in the step S3 in deionized water, adding activated carbon for reflux and decoloration, adding concentrated ammonia water to adjust the pH to be approximately equal to 10, and filtering to collect the generated solid;
and Z2, recrystallizing the solid obtained in the step T3 by using an absolute ethyl alcohol-ethyl acetate mixed solvent to obtain the light yellow crystal isoalbutine analogue.
Preferably, the solvent in the step Y1 is absolute methanol, absolute ethanol or 95% ethanol, and the molar ratio of the levofloxacin to the potassium borohydride is 1 (1-3).
Preferably, the molar ratio of the 2, 3-dihydroquinolin-4-one to the phenylhydrazines in the step T1 is 1 (1-2), the phenylhydrazines are phenylhydrazine, p-methylphenylhydrazine, m-methylphenylhydrazine, o-methylphenylhydrazine, p-fluorophenylhydrazine, m-fluorophenylhydrazine or m-fluorosulfonylaminophenylhydrazine, the cyclization catalyst in the step T2 is concentrated hydrochloric acid, concentrated sulfuric acid, phosphoric acid, polyphosphoric acid, glacial acetic acid or trifluoroacetic acid, and the reflux reaction time is 10-24 h.
An application of isohederin analogue in preparing antituberculosis drugs is provided.
Preferably, the isoalbuterone analogue is used for preparing medicine for inhibiting mycobacterium tuberculosis, wherein the mycobacterium tuberculosis is H37Ra or H37Rv。
The invention has the beneficial effects that:
1. the isoleucinine analogue of the invention reserves the predominant skeleton of isoleucinine-indoloquinoline mother nucleus, and simultaneously has the characteristic structure of fluoroquinolone medicaments, namely quinoline ring, especially as the effective modifying group of fluoroquinolone medicaments, and the hydrophilic basic piperazinyl is used as the modifying group of the indoloquinoline mother nucleus, thereby not only effectively improving the water solubility of the isoleucinine and improving the bioavailability, being beneficial to the development of drug properties, but also increasing the medicament osmosis effect by introducing fluorine atoms, and realizing the effects of enhancing the efficiency and reducing toxicity and resisting drug resistance.
2. The indoloquinoline parent nucleus and the quinoline ring in the isoleucinine analogue realize the complementation and the activity superposition of different structural pharmacophores, and the in vitro antitubercular activity test result in an experimental example shows that the compound has better growth inhibition activity on a test tuberculosis strain, the activity of part of the compound is equivalent to that of a control isoniazid, and the compound has the advantages of drug resistance, lower cytotoxicity, excellent in vitro inhibition activity on the growth of tubercle bacillus, and can be further developed as a novel antitubercular medicament with the structural characteristics of indoloquinoline.
3. According to the preparation method, levofloxacin is used for preparing 2, 3-dihydroquinoline-4-ketone through reduction decarboxylation reaction and potassium borohydride, then 2, 3-dihydroquinoline-4-ketone and phenylhydrazine are used for preparing the isoalbuterol analogue through a Fischer indole synthesis method, effective chemical construction from a fluoroquinolone structure to an indoloquinoline skeleton is achieved, a new approach of structural modification of isoalbuterol is expanded, and complementation of the advantageous structures of a fluoroquinolone medicine and natural indoloquinoline alkaloids is achieved.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be obtained by a person skilled in the art without inventive effort based on the embodiments of the present invention, are within the scope of the present invention.
Example 1
An isoalburnine analogue has a chemical structural general formula shown in formula I:
Figure BDA0003321131400000071
in this example, where the substituent R in formula I is H, the chemical structure of S-2-fluoro-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline is:
Figure BDA0003321131400000081
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-1), and specifically includes the following steps:
s1, carrying out reduction decarboxylation reaction on levofloxacin shown in the formula II serving as a raw material and potassium borohydride to obtain 2, 3-dihydroquinolin-4-one shown in the formula III.
Figure BDA0003321131400000082
Specifically, the method comprises the following steps: y1, mixing levofloxacin and a solvent to prepare a suspension, slowly adding potassium borohydride into the suspension in a fractional manner under stirring at normal temperature, heating the mixed reactant in a water bath, and stirring and refluxing to react until the levofloxacin disappears to obtain a mixed solution; y2, placing the mixed solution obtained in the step Y1 to room temperature, and evaporating the solvent in the mixed solution by using an evaporator to obtain a residue; y3, adding the remainder obtained in the step Y2 into deionized water, mixing, adjusting the pH to be approximately equal to 2 by using concentrated hydrochloric acid, adding activated carbon for decoloring, adjusting the pH to be approximately equal to 10 by using sodium hydroxide with the mass concentration of 30%, and standing to separate out a solid; y4, and recrystallizing the solid precipitated in the step Y3 by hot water and n-hexane in sequence to obtain the 2, 3-dihydroquinolin-4-one.
In this embodiment, the method specifically includes: 20.0g (55.0mmol) of S- (-) -1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one-3-carboxylic acid II is suspended in 500mL of anhydrous methanol, 6.0g (110.0mmol) of potassium borohydride is slowly added in portions while stirring at normal temperature, the reaction mixture is heated in a water bath, and the reaction mixture is stirred and refluxed until the raw material II disappears. The mixture was left at room temperature, and the solvent was evaporated under reduced pressure by a rotary evaporator. And adding 500mL of deionized water into the residue, adjusting the pH value to be approximately equal to 2.0 by using concentrated hydrochloric acid, adding a proper amount of activated carbon for decolorization, adjusting the pH value of the filtrate to be approximately equal to 10.0 by using a sodium hydroxide solution with the mass concentration of 30%, and standing to separate out a solid. And recrystallizing the crude product by using hot water and n-hexane in sequence to obtain S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -2, 3-dihydro-quinolin-4 (1H) -one shown in a formula III, wherein the yield is 37.4%, and m.p.104-106 ℃.1H NMR(400MHz,CD3Cl)δ：6.97(1H, d,5-H),4.21～4.11(2H,m,2-H),3.42～3.18(7H，m，OCH2CHN and piperazine-H), 2.67-2.36 (6H, m, 3-H and piperazine), 2.23(3H, s, N-CH)3)，1.36(3H，d，CH3)； MS(m/z)：320[M+H]+Calculating (C)17H22FN3O2)：319.38。
S2, preparing the cryptolepine alkaloid with the mother nucleus structure characteristics of the indoloquinoline by the Fischer indole synthesis method by using the 2, 3-dihydroquinoline-4-ketone and the phenylhydrazine obtained in the step S1. Specifically, the method comprises the following steps: t1, dissolving the 2, 3-dihydroquinolin-4-one obtained in the step S1 in a solvent, adding a phenylhydrazine, and stirring at normal temperature until the 2, 3-dihydroquinolin-4-one disappears to obtain a mixed solution; t2, adding a cyclization catalyst into the mixed solution obtained in the step T1 dropwise, carrying out heating reflux reaction, standing to room temperature, and filtering to collect the generated albophylline alkaloid with the mother nucleus structure characteristics of indoloquinoline.
In this embodiment, the method specifically includes: 1.0g (3.0mmol) of S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one III was dissolved in 15mL of absolute ethanol, 0.50g (4.6 mmol) of phenylhydrazine was added thereto, and the reaction mixture was stirred at room temperature for 12 hours to form a precipitate. Concentrated hydrochloric acid (0.50mL) was added, and the reaction was mixed and refluxed for 10 hours, and left overnight. The resulting solids were collected by filtration. The solid is the bynine alkaloid with the mother nucleus structure characteristic of the indoloquinoline.
S3, carrying out post-treatment on the Sinomenine alkaloid with the mother nucleus structure characteristic of the indoloquinoline obtained in the step S2 to obtain the isoSinomenine analogue as claimed in claim 1 or 2. Specifically, the method comprises the following steps: z1, dissolving the cryptolepine alkaloid with the mother nucleus structure characteristics of the indoloquinoline obtained in the step S3 in deionized water, adding activated carbon for reflux and decoloration, adding concentrated ammonia water to adjust the pH to be approximately equal to 10, and filtering to collect the generated solid; and Z2, recrystallizing the solid obtained in the step T3 by using an absolute ethyl alcohol-ethyl acetate mixed solvent to obtain the light yellow crystal isoalbutine analogue.
In this embodiment, the method specifically includes: dissolving the solid with 50mL of deionized water, adding a proper amount of active carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. Filter set generationDrying the solid, and recrystallizing the dried solid by using an absolute ethyl alcohol-ethyl acetate mixed solvent (v: v ═ 3:1), so as to obtain a light yellow crystal target compound, namely the formula I-1, wherein the yield is 42.5%, and m.p.216-218 ℃.1H NMR(400MHz,CD3Cl)δ：1.65(3H,d，CH3)，2.32(3H，s，N-CH3) 3.07 to 3.68(8H, m, piperazine-H), 4.46 to 4.74(3H, m, O-CH)2CH-N)， 6.89～7.56(4H，m，Ph-H)，7.84(1H，d，1-H)，8.86(1H，s，6-H)；MS(m/z)： 391[M+H]+Calculating (C)23H23FN4O)：390.46。
Example 2
An isofraxinine analog, which is different from example 1 in that the substituent R in formula I is methoxy, the chemical structure of isofraxinine analog, S-2-fluoro-8-methoxy-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is:
Figure BDA0003321131400000101
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-2), and specifically includes the following steps: dissolving 1.0g (3.0mmol) of S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one III in 15mL of absolute ethyl alcohol, adding 0.62g (4.5mmol) of p-methoxyphenylhydrazine, and stirring at normal temperature for 12 hours to react, wherein a remarkable precipitate is generated. Concentrated hydrochloric acid (0.50mL) was added, and the reaction was mixed and refluxed for 10 hours, and left overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. The resulting solid was collected by filtration, dried, and recrystallized from an absolute ethyl alcohol-ethyl acetate mixed solvent (v: v ═ 5:1) to obtain a pale yellow crystalline target compound of formula I-2, yield 43.8%, m.p.225 to 227 ℃.1H NMR(400MHz,CD3Cl)δ：1.65(3H,d,CH3),2.32(3H，s，N-CH3) 3.15 to 3.76(8H, m, piperazine-H), 3.88(3H, s, OCH)3)，4.46～4.84(3H，m，O-CH2CH-N)，7.36～7.78 (3H，m，Ph-H)，8.52(1H，d，1-H),9.10(1H，s，6-H)；MS(m/z)：421[M+H]+Calculating (C)24H25FN4O2)：420.49。
It is worth noting that in this example, the process for preparing S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one is essentially the same as in example 1, except that in this example, the molar ratio of levofloxacin to potassium borohydride is set to 1: 2, anhydrous methanol used in example 1 as a solvent was replaced with anhydrous ethanol as a solvent.
Example 3
An isofraxinine analog, which is different from example 1 in that the substituent R in formula I is methoxy, the chemical structure of isofraxinine analog, S-2-fluoro-9-methoxy-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is:
Figure BDA0003321131400000111
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-3), and specifically includes the following steps: 1.0g (3.0mmol) of S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one III was dissolved in 15mL of absolute ethanol, and 0.83g (6.0mmol) of m-methoxyphenylhydrazine was added thereto, and the reaction mixture was stirred at room temperature for 20 hours to form a precipitate. Concentrated hydrochloric acid (0.50mL) was added and the reaction was mixed and refluxed for 18h and allowed to stand overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. The resulting solid was collected by filtration, dried, and recrystallized from an absolute ethyl alcohol-ethyl acetate mixed solvent (v: v ═ 3:1) to obtain a pale yellow crystalline target compound of formula I-3, yield 35.7%, m.p.215 to 217 ℃.1H NMR(400MHz, CD3Cl)δ：1.66(3H,d,CH3),2.32(3H，s，N-CH3) 3.15 to 3.76(8H, m, piperazine-H), 3.88(3H, s, OCH)3)，4.45～4.86(3H，m，O-CH2CH-N)，7.38～8.04(3H，m，Ph-H)， 8.52(1H，d，1-H),9.07(1H，s，6-H)；MS(m/z)：421[M+H]+Calculating (C)24H25FN4O2)： 420.49。
It is worth noting that in this example, the process for preparing S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one is essentially the same as in example 1, except that in this example, the molar ratio of levofloxacin to potassium borohydride is set to 1: 1, the absolute methanol used in example 1 as solvent was replaced with 95% ethanol as solvent.
Example 4
An isofraxinine analog, which is different from example 1 in that the substituent R in formula I is methoxy, the chemical structure of isofraxinine analog, S-2-fluoro-10-methoxy-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is:
Figure BDA0003321131400000121
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-4), and specifically includes the following steps: 1.0g (3.0mmol) of S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one III was dissolved in 15mL of absolute ethanol, 0.72g (5.0mmol) of o-methoxyphenylhydrazine was added thereto, and the reaction mixture was stirred at room temperature for 20 hours to form a precipitate. Concentrated hydrochloric acid (0.50mL) was added and the reaction was mixed and refluxed for 15h and allowed to stand overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. The generated solid is collected by filtration, dried and recrystallized by an absolute ethyl alcohol-ethyl acetate mixed solvent (v: v ═ 3:1), and a light yellow crystal target compound, namely the formula I-4 is obtained, the yield is 32.6%, and m.p.214-216 ℃.1H NMR(400MHz, CD3Cl)δ：1.67(3H,d,CH3),2.32(3H，s，N-CH3) 3.15 to 3.72(8H, m, piperazine-H), 3.87(3H,s，OCH3)，4.46～4.84(3H，m，O-CH2CH-N)，7.46～8.07(3H，m，Ph-H)， 8.68(1H，d，1-H),9.04(1H，s，6-H)；MS(m/z)：421[M+H]+calculating (C)24H25FN4O2)： 420.49。
It is worth noting that in this example, the process for preparing S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one is essentially the same as in example 1, except that in this example, the molar ratio of levofloxacin to potassium borohydride is set to 1: 2, the absolute methanol used in example 1 as solvent was replaced with 95% ethanol as solvent.
Example 5
An isofolinine analogue, which is different from example 1 in that the substituent R in formula I is methyl, the chemical structure of isofolinine analogue, S-2-fluoro-8-methyl-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is:
Figure BDA0003321131400000131
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-5), and specifically includes the following steps: dissolving 1.0g (3.0mmol) of S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one shown in formula III in 15mL of absolute ethanol, adding 0.70g (5.7mmol) of p-methylphenylhydrazine, and reacting for 22H under stirring at normal temperature to obtain a remarkable precipitate. Concentrated hydrochloric acid (0.50mL) was added and the reaction was mixed and refluxed for 12h and allowed to stand overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. The resulting solid was collected by filtration, dried, and recrystallized from an absolute ethanol-ethyl acetate mixed solvent (v: v ═ 5:1) to give a pale yellow crystalline target compound of formula I-5, yield 42.6%, m.p.213 to 215 ℃.1H NMR(400MHz,CD3Cl)δ：1.65(3H,d,CH3),2.26(3H，s，Ph-CH3)， 2.30(3H，s，N-CH3) 3.12 to 3.68(8H, m, piperazine-H), 4.45 to 4.76(3H, m, O-CH)2CH-N)， 7.18～7.76(3H，m，Ph-H)，8.56(1H，d，1-H),8.87(1H，s，6-H)；MS(m/z)： 405[M+H]+Calculating (C)24H25FN4O)：404.49。
It is worth noting that in this example, the process for preparing S-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one is essentially the same as in example 1, except that in this example, the molar ratio of levofloxacin to potassium borohydride is set to 1: 3, anhydrous methanol used in example 1 as a solvent was replaced with anhydrous ethanol as a solvent.
Example 6
An isofraxinine analog, which is different from example 1 in that the substituent R in formula I is F atom, the chemical structure of isofraxinine analog, namely S-2, 8-difluoro-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is as follows:
Figure BDA0003321131400000141
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-6), and specifically includes the following steps: s-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one of the formula III 1.0g (3.0mmol) was dissolved in 15mL of absolute ethanol, and p-fluorophenylhydrazine 0.60g (4.8mmol) was added thereto, and the reaction was stirred at room temperature for 17 hours to form a precipitate. Concentrated hydrochloric acid (0.50mL) was added and the reaction was mixed and refluxed for 15h and allowed to stand overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. And (3) collecting the generated solid by filtration, drying, and recrystallizing by using an absolute ethyl alcohol-ethyl acetate mixed solvent (v: v ═ 6:1) to obtain a light yellow crystal target compound, namely the formula I-6, wherein the yield is 52.6%, and m.p. is 226-228 ℃.1H NMR(400MHz, CD3Cl)δ：1.67(3H,d,CH3),2.34(3H，s，N-CH3) 3.17 to 3.76(8H, m, piperazine-H), 4.56 to 4.84(3H, m, O-CH)2CH-N)，7.48～8.12(3H，m，Ph-H)，8.26(1H，d，1-H), 9.12(1H，s，6-H)；MS(m/z)：409[M+H]+Calculating (C)23H22F2N4O)：408.45。
Example 7
An isofraxinine analog, which is different from example 1 in that the substituent R in formula I is F atom, the chemical structure of isofraxinine analog, namely S-2, 9-difluoro-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is as follows:
Figure BDA0003321131400000142
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-7), and specifically includes the following steps: s-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one formula III 1.0g (3.0mmol) is dissolved in 15mL of absolute ethanol, 0.66g (5.2mmol) of m-fluorophenylhydrazine is added, and the reaction is stirred at normal temperature for 16H, so that a remarkable precipitate is generated. Concentrated hydrochloric acid (0.50mL) was added and the reaction was mixed and refluxed for 18h and allowed to stand overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. The resulting solid was collected by filtration, dried, and recrystallized from an absolute ethyl alcohol-ethyl acetate mixed solvent (v: v ═ 4:1) to give a pale yellow crystalline target compound of formula I-7, yield 45.6%, m.p.213 to 215 ℃.1H NMR(400MHz,CD3Cl)δ：1.66(3H,d,CH3),2.32(3H，s，N-CH3) 3.13 to 3.68(8H, m, piperazine-H), 4.48 to 4.86(3H, m, O-CH)2CH-N)，7.46～8.17(3H，m，Ph-H)，8.52 (1H，d，1-H),8.96(1H，s，6-H)；MS(m/z)：409[M+H]+Calculating (C)23H22F2N4O)： 408.45。
Example 8
An isofraxinine analog, which is different from example 1 in that the substituent R in formula I is chlorine atom, the chemical structure of isofraxinine analog, S-2-fluoro-8-chloro-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is:
Figure BDA0003321131400000151
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-8), and specifically includes the following steps: s-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one of the formula III 1.0g (3.0mmol) was dissolved in 15mL of absolute ethanol, 0.74g (5.2mmol) of p-chlorophenylhydrazine was added thereto, and the reaction mixture was stirred at room temperature for 17 hours, whereby a large amount of precipitate was formed. Concentrated hydrochloric acid (0.50mL) was added, and the reaction was mixed and refluxed for 10 hours, and left overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. The resulting solid was collected by filtration, dried, and recrystallized from an absolute ethanol-ethyl acetate mixed solvent (v: v ═ 6:1) to give a pale yellow crystalline target compound of formula I-8, yield 43.6%, m.p.212 to 214 ℃.1H NMR(400MHz,CD3Cl)δ：1.66(3H,d,CH3),2.35(3H，s，N-CH3) 3.18 to 3.74(8H, m, piperazine-H), 4.53 to 4.86(3H, m, O-CH)2CH-N)，7.53～8.15(3H，m，Ph-H)，8.72 (1H，d，1-H),9.03(1H，s，6-H)；MS(m/z)：425(Cl35)[M+H]+，427(Cl37)[M+H]+Calculating (C)23H22ClFN4O)：424.91。
Example 9
An isofraxinine analog, which is different from example 1 in that the substituent R in formula I is chlorine atom, the chemical structure of isofraxinine analog, S-2-fluoro-9-chloro-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is:
Figure BDA0003321131400000161
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-9), and specifically includes the following steps: s-1, 8-isopropoxy-6-fluoro-7- (4-methylpiperazin-1-yl) -quinolin-4 (1H) -one of the formula III 1.0g (3.0mmol) was dissolved in 15mL of absolute ethanol, and 0.70g (5.0mmol) of m-chlorophenylhydrazine was added thereto, and the reaction mixture was stirred at room temperature for 17 hours to form a precipitate. Concentrated hydrochloric acid (0.50mL) was added and the reaction was mixed and refluxed for 16h and allowed to stand overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. The resulting solid was collected by filtration, dried, and recrystallized from an absolute ethyl alcohol-ethyl acetate mixed solvent (v: v ═ 6:1) to give a pale yellow crystalline target compound of formula I-9, yield 36.4%, m.p.210 to 212 ℃.1H NMR(400MHz, CD3Cl)δ：1.67(3H,d,CH3),2.32(3H，s，N-CH3) 3.16 to 3.75(8H, m, piperazine-H), 4.53 to 4.86(3H, m, O-CH)2CH-N)，7.52～8.16(3H，m，Ph-H)，8.68(1H，d，1-H), 9.06(1H，s，6-H)；MS(m/z)：425(Cl35)[M+H]+，427(Cl37)[M+H]+Calculating (C)23H22ClFN4O)：424.91。
Example 10
An isoleucinine analog, which is different from example 1 in that the substituent R in formula I is a sulfonamide group, the chemical structure of isoleucinine analog, S-2-fluoro-8-sulfonamide-3- (4-methylpiperazin-1-yl) -4, 5-isopropoxy-5H-indolo [3,2-c ] quinoline, is:
Figure BDA0003321131400000171
in this example, a preparation method of an isoalbutine analogue from levofloxacin to isoalbutine analogue is used for preparing the isoalbutine analogue (I-10), and specifically includes the following steps: taking S-1, 8-isopropoxy-6-fluorine-7- (4-Methylpiperazin-1-yl) -quinolin-4 (1H) -one of the formula III 1.0g (3.0mmol) was dissolved in 15mL of anhydrous ethanol, 0.67g (3.6mmol) of p-chlorosulfonylaminophenhydrazide was added thereto, and the reaction was stirred at room temperature for 24 hours to form a large amount of precipitate. Concentrated hydrochloric acid (0.50mL) was added and the reaction was mixed and refluxed for 20h and allowed to stand overnight. And (3) filtering and collecting the generated solid, dissolving the solid in 50mL of deionized water, adding a proper amount of activated carbon, and refluxing and decoloring for 1 h. Hot filtration, pH of filtrate adjusted with ammonia about 10.0. And (3) collecting the generated solid by filtration, drying, and recrystallizing by using an absolute ethyl alcohol-ethyl acetate mixed solvent (v: v ═ 8:1) to obtain a light yellow crystal target compound, namely the formula I-10, wherein the yield is 52.4%, and m.p. is 232-234 ℃.1H NMR(400MHz,CD3Cl)δ：1.68(3H,d,CH3),2.32(3H，s，N-CH3) 3.25 to 3.84(8H, m, piperazine-H), 4.57 to 4.86(3H, m, O-CH)2CH-N), 7.56-8.17 (5H, m, Ph-H and SO)2NH2)，8.65(1H，d，1-H),9.12(1H，s，6-H)；MS(m/z)：470[M+H]+Calculating (C)23H24FN5O3S)：469.54。
The invention also provides application of the isoalbutine analogue in preparing anti-tuberculosis drugs, in particular to application of the isoalbutine analogue in preparing drugs for inhibiting mycobacterium tuberculosis, wherein the mycobacterium tuberculosis is H37Ra or H37Rv, the following experimental examples of the use of isospergualin analogs in the preparation of anti-tubercular drugs are described in detail.
Examples of the experiments
First, the in vitro anti-tubercle bacillus activity assay of the isoalbugine analogs provided in examples 1 to 10
1. Experimental reagent
Positive control substances Isoniazide (INH) and Levofloxacin (Levofloxacin) were purchased from the institute of food and drug, hannan province; 7H9 liquid culture medium was purchased from Difco, USA. Under the aseptic condition, a positive control and the samples of the examples 1 to 10 are prepared into a 4mg/mL solution by using dimethyl sulfoxide (DMSO), the solution is filtered by a 0.22 mu m filter membrane after being dissolved sufficiently by ultrasound, and the filtrate is used as a stock solution and is stored at the temperature of-20 ℃ for standby application (when in use, the concentration of the DMSO in a culture solution is less than 0.5 percent in order to avoid the influence of the DMSO on the experimental result).
2. Tuberculosis strain
The experimental tuberculosis strains are respectively a mycobacterium tuberculosis standard strain H37Ra(ATCC25177)、 H37The clinical separated drug-resistant mycobacterium tuberculosis of Rv (ATCC27294) and 3 strains are respectively numbered as H6, H7 and H10, and are provided by the Henan province disease prevention and control center and provide the measurement of experimental data. Wherein, H6 and H7 are multi-drug resistant strains for isoniazid, rifampicin, ethambutol, streptomycin and ofloxacin, and H10 is a drug resistant strain for isoniazid and rifampicin.
3. Experimental methods
1) Preparation of a strain suspension: taking out the to-be-detected tubercle bacillus cultured for 2-3 weeks, inoculating into a sterilized small bottle, uniformly mixing to form milk, diluting with normal saline, preparing the bacterial liquid into 1mg/mL bacterial liquid by turbidimetric reaction with a NO.1 McLee standard turbidimetric tube, and diluting with normal saline to 1 × 105The CFU is ready for use.
2) To a 96-well plate, 200. mu.L of a solution of the compound to be tested at an appropriate concentration was added (the compound to be tested was diluted to 200. mu.g/mL with sterile 7H9 broth), and then the compound to be tested was further diluted as necessary (fold-by-fold dilution to 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39, 0.195, 0.097, 0.048, 0.024, 0.012. mu.g/mL), and drug-free control wells were set.
3) Adding the diluted bacteria solution into all detection wells and drug-free facing wells, placing the plates in a constant temperature incubator, each plate being at 37 deg.C and 5% CO2Cultured under the conditions for 21 days. The lowest concentration at which no bacterial strain grows is observed by naked eyes through a microscope at 40 times is the Minimum Inhibitory Concentration (MIC) of the drug. Meanwhile, isoniazid and levofloxacin are used as positive controls, and DMSO and a culture solution without any compound are used as negative controls. Each data was measured in triplicate and averaged, and the results are shown in Table 1.
TABLE 1 in vitro antitubercular Activity (MIC) of test samples
Figure BDA0003321131400000191
The results in Table 1 show that, of the compounds provided in examples 1 to 10, examples 1, 4, 6, 7 and 10 are H37Ra and H37The MIC values of two standard strains of the Rv mycobacterium tuberculosis are lower than that of a control levofloxacin, and particularly, the activities of the standard strains of the Rv mycobacterium tuberculosis are equivalent to those of isoniazid, so that the standard strains of the Rv mycobacterium tuberculosis show better in-vitro anti-tubercle bacillus activity. Meanwhile, the MIC values of the compounds provided in examples 1-10 on 3 clinically isolated drug-resistant strains H6, H7 and H10 are lower than those of control levofloxacin or isoniazid, and the compounds show better anti-drug resistance activity.
Second, in vitro cytotoxicity assay of examples 1 to 10
1. Experimental reagent
Positive control substances Isoniazide (INH) and Levofloxacin (Levofloxacin) were purchased from the institute of food and drug, hannan province; normal cells were VerO, a Vero cell line, purchased from Shanghai Tong Seiki Seisakusho Biotech, Ltd. RPMI, Trypsin (TRGPSIN) and fetal calf serum were purchased from Hangzhou ilex bioengineering materials, Inc.; brominating- (4,5) -dimethyl-2-thiazole-2, 5-diphenyl tetrazole (MTT, AMRESCO split charging); sodium Dodecyl Sulfate (SDS), sodium dihydrogen phosphate purchased from Tianjin department Europe chemical reagent development center; ethylenediaminetetraacetic acid disodium salt (EDTA) and dimethyl sulfoxide (DMSO) were purchased from Tianjin Deen chemical Co., Ltd.
2. Preparation of test solution
Under the aseptic condition, the positive reference substance and the test substances of the examples I-1 to I-10 are prepared into 1.0 multiplied by 10 by dimethyl sulfoxide (DMSO)-4mol·L-112 stock solutions with concentration, and then diluting the stock solutions with 5 concentration gradients (0.1, 1.0, 5.0, 10.0, 50.0 μmol. L) by using 10% calf serum RPMI-1640 culture solution-1) The working solution is fully dissolved by ultrasonic waves and then filtered by a filter membrane of 0.22 mu m, and the filtrate is taken as a test solution and is stored at the temperature of minus 20 ℃ for standby.
3. Experimental method (MTT method)
Taking a VERO African green monkey kidney cell strain in logarithmic growth phase to6000 cells per well were seeded on a 96-well plate, then the working solution having 5 concentration gradients of the above 12 samples was added, and after 48 hours, 5 g.L per well was added–1mu.L of MTT (thiazole blue) solution was added, and after further culturing for 4 hours, 100. mu.L of a 10% by mass Sodium Dodecyl Sulfate (SDS) solution was added. After 24 hours of incubation, the absorbance (OD) was measured at a wavelength of 570nm using a microplate reader. The inhibition rate of cell proliferation is calculated according to the formula:
inhibition rate [ (1-experimental OD value)/control OD value ] × 100%
Then, linear regression is carried out on the VERO cell inhibition rate corresponding to each concentration according to the pair value of each concentration of each sample to obtain a dose-effect equation, and the half Inhibition Concentration (IC) of the sample to the experimental VERO cell is calculated from the obtained dose-effect equation50) (ii) a Each data was measured in triplicate and averaged, the results are shown in Table 2.
TABLE 2 in vitro VERO cytotoxicity assay (IC) of test samples50)
Figure BDA0003321131400000211
Table 2 results show that the compounds provided in examples 1-10 have half the growth Inhibitory Concentration (IC) on VERO cells50) Compared with the positive control levofloxacin, the compound has lower cytotoxicity and IC50IC higher than positive isoniazid50The values indicate that the toxicity of the compounds provided in examples 1-10 is lower than that of the positive control isoniazid.
In conclusion, the compounds provided in embodiments 1 to 10 have not only better anti-tubercle bacillus activity but also potential anti-drug resistance activity in vitro, and exhibit lower cytotoxic effects. Based on the new drug research rule, the levofloxacin-isoalbutine analogue is expected to develop an anti-tuberculosis drug with high efficiency and low toxicity.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.

Claims (10)

1. An isoalburnine analogue is characterized in that the chemical structural general formula is shown as formula I:
Figure FDA0003321131390000011
the substituent R in the formula I can be independently hydrogen atom-H, methoxyl-OCH3methyl-CH3Fluorine atom-F, chlorine atom-Cl or xanthylamino-SO2NH2。
2. The isoalburnine analogue of claim 1, wherein the isoalburnine analogue has the chemical formula:
Figure FDA0003321131390000012
Figure FDA0003321131390000021
3. a preparation method of an analogue from levofloxacin to isoleucinine is characterized by comprising the following steps:
s1, carrying out reduction decarboxylation reaction on levofloxacin shown in a formula II serving as a raw material and potassium borohydride to obtain 2, 3-dihydroquinolin-4-one shown in a formula III;
Figure FDA0003321131390000031
s2, preparing the cryptolepine alkaloid with the mother nucleus structure characteristic of the indoloquinoline by the Fischer indole synthesis method by using the 2, 3-dihydroquinoline-4-ketone and the phenylhydrazine obtained in the step S1;
Figure FDA0003321131390000032
s3, carrying out post-treatment on the Sinomenine alkaloid with the mother nucleus structure characteristic of the indoloquinoline obtained in the step S2 to obtain the isoSinomenine analogue as claimed in claim 1 or 2.
4. The process for preparing an analog of levofloxacin-isoleucinine according to claim 3, wherein the step S1 comprises the following steps:
y1, mixing levofloxacin and a solvent to prepare a suspension, slowly adding potassium borohydride into the suspension in a fractional manner under stirring at normal temperature, heating the mixed reactant in a water bath, and stirring and refluxing to react until the levofloxacin disappears to obtain a mixed solution;
y2, placing the mixed solution obtained in the step Y1 to room temperature, and evaporating the solvent in the mixed solution by using an evaporator to obtain a residue;
y3, adding the remainder obtained in the step Y2 into deionized water, mixing, adjusting the pH to be approximately equal to 2 by using concentrated hydrochloric acid, adding activated carbon for decoloring, adjusting the pH to be approximately equal to 10 by using sodium hydroxide with the mass concentration of 30%, and standing to separate out a solid;
y4, and recrystallizing the solid precipitated in the step Y3 by hot water and n-hexane in sequence to obtain the 2, 3-dihydroquinolin-4-one.
5. The process for preparing an analog of levofloxacin-isoleucinine according to claim 3, wherein the step S2 comprises the following steps:
t1, dissolving the 2, 3-dihydroquinolin-4-one obtained in the step S1 in absolute ethyl alcohol, adding phenylhydrazines, and stirring at normal temperature until the 2, 3-dihydroquinolin-4-one disappears to obtain a mixed solution;
t2, adding a cyclization catalyst into the mixed solution obtained in the step T1 dropwise, carrying out heating reflux reaction, standing to room temperature, and filtering to collect the generated albophylline alkaloid with the mother nucleus structure characteristics of indoloquinoline.
6. The process for preparing an analog of levofloxacin-isoleucinine according to claim 3, wherein the step S3 comprises the following steps:
z1, dissolving the cryptolepine alkaloid with the mother nucleus structure characteristics of the indoloquinoline obtained in the step S3 in deionized water, adding activated carbon for reflux and decoloration, adding concentrated ammonia water to adjust the pH to be approximately equal to 10, and filtering to collect the generated solid;
and Z2, recrystallizing the solid obtained in the step T3 by using an absolute ethyl alcohol-ethyl acetate mixed solvent to obtain the light yellow crystal isoalbutine analogue.
7. The preparation method of analogs of levofloxacin and isoleucinine as claimed in claim 4, wherein the solvent in step Y1 is absolute methanol, absolute ethanol or 95% ethanol, and the molar ratio of levofloxacin and potassium borohydride is 1 (1-3).
8. The process of claim 5, wherein the molar ratio of 2, 3-dihydroquinolin-4-one to phenylhydrazines in step T1 is 1 (1-2), the phenylhydrazines are phenylhydrazine, p-methylphenylhydrazine, m-methylphenylhydrazine, o-methylphenylhydrazine, p-fluorophenylhydrazine, m-fluorophenylhydrazine or m-fluorosulfonylaminophenylhydrazine, the cyclization catalyst in step T2 is concentrated hydrochloric acid, concentrated sulfuric acid, phosphoric acid, polyphosphoric acid, glacial acetic acid or trifluoroacetic acid, and the reflux reaction time is 10-24 h.
9. Use of the isoalbuterol analogue according to any one of claims 1, 2, 4 to 8 in the manufacture of an anti-tuberculosis medicament.
10. Use of isoalbuterone analogues according to claim 9 for the preparation of antitubercular medicaments, characterized in that said isoalbuterone analogues are used for the preparation of a medicament for inhibiting the branching of tuberculosisThe bacillus drug is H37Ra or H37Rv。
CN202111246352.1A 2021-10-26 2021-10-26 Preparation method and application of isofraxine analogue from levofloxacin to isofraxine analogue Active CN113801140B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111246352.1A CN113801140B (en) 2021-10-26 2021-10-26 Preparation method and application of isofraxine analogue from levofloxacin to isofraxine analogue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111246352.1A CN113801140B (en) 2021-10-26 2021-10-26 Preparation method and application of isofraxine analogue from levofloxacin to isofraxine analogue

Publications (2)

Publication Number Publication Date
CN113801140A true CN113801140A (en) 2021-12-17
CN113801140B CN113801140B (en) 2023-05-23

Family

ID=78937842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111246352.1A Active CN113801140B (en) 2021-10-26 2021-10-26 Preparation method and application of isofraxine analogue from levofloxacin to isofraxine analogue

Country Status (1)

Country Link
CN (1) CN113801140B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402902A (en) * 2014-12-15 2015-03-11 河南大学 Chirality 7-(piperazine-substituted pyrazol aldehyde condensation isoniazide) fluoroquinolone carboxylic acid derivative as well as preparation method and application thereof
CN111393453A (en) * 2019-11-20 2020-07-10 河南大学 Acrylketone derivative of levofloxacin, and preparation method and application thereof
CN111647004A (en) * 2019-11-20 2020-09-11 河南大学 Propenone derivative for removing N-methylofloxacin and preparation method and application thereof
CN112824416A (en) * 2019-11-20 2021-05-21 河南大学 Propenone derivative for removing N-methyllevofloxacin, and preparation method and application thereof
CN112824415A (en) * 2019-11-20 2021-05-21 河南大学 Ofloxacin acrylketone derivative and preparation method and application thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104402902A (en) * 2014-12-15 2015-03-11 河南大学 Chirality 7-(piperazine-substituted pyrazol aldehyde condensation isoniazide) fluoroquinolone carboxylic acid derivative as well as preparation method and application thereof
CN111393453A (en) * 2019-11-20 2020-07-10 河南大学 Acrylketone derivative of levofloxacin, and preparation method and application thereof
CN111647004A (en) * 2019-11-20 2020-09-11 河南大学 Propenone derivative for removing N-methylofloxacin and preparation method and application thereof
CN112824416A (en) * 2019-11-20 2021-05-21 河南大学 Propenone derivative for removing N-methyllevofloxacin, and preparation method and application thereof
CN112824415A (en) * 2019-11-20 2021-05-21 河南大学 Ofloxacin acrylketone derivative and preparation method and application thereof

Also Published As

Publication number Publication date
CN113801140B (en) 2023-05-23

Similar Documents

Publication Publication Date Title
RU2633694C2 (en) Dyetherned phenylaminopyrimidine and pharmaceutical composition containing such connection
WO2016090257A1 (en) Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
JP2019526605A (en) Crystal form and salt form of substituted 2-H-pyrazole derivative and method for producing the same
FR2941948A1 (en) AZAINDOLE DERIVATIVES AS INHIBITOR OF ABL KINASE PROTEINS AND SRC
JP2010536807A (en) Indropyridine as an inhibitor of kinesin spindle protein (EG5)
AU2022379782A1 (en) Synthesis, preparation method and use of shp2 and cdk4/6 dual-target inhibitory compound
CN113816959A (en) Isochrysine analogue prepared from enrofloxacin as raw material and preparation method and application thereof
CN107286220B (en) 1,2, 4-triazole coupled dihydromyricetin derivative and preparation method and application thereof
CN109369623B (en) Substituted 1,2,3 triazole diaryl pyrimidine derivative and preparation method and application thereof
CN114276369B (en) Preparation method and application of isobaicine analogue from ofloxacin to isobaicine analogue
CN113801140B (en) Preparation method and application of isofraxine analogue from levofloxacin to isofraxine analogue
CN114276346B (en) Isobanchamine analogue, preparation method and application of same from fleroxacin to
CN113956251B (en) Preparation method and application of isofraxine analogue from lomefloxacin to isofraxine analogue
CN110357905B (en) Macrocyclic derivatives as protein kinase inhibitors, and preparation method and application thereof
CN113912603B (en) Preparation method and application of isofraxine analogue from ciprofloxacin to isofraxine analogue
CN113896727B (en) Preparation method and application of isofraxine analogue from gatifloxacin to isofraxine analogue
CN113788828B (en) Preparation method and application of isofraxine analogue from norfloxacin to isofraxine analogue
CN107936024B (en) Anaplastic lymphoma kinase inhibitor and preparation method and application thereof
CN113816958A (en) Isoleucinine analogue prepared from pefloxacin as raw material, and preparation method and application thereof
CN113999250A (en) Isoleucinine analogue prepared from ofloxacin as raw material, and preparation method and application thereof
CN113968857A (en) Isochrysine analogue prepared from enoxacin as raw material and preparation method and application thereof
CN113816976A (en) Isochrysine analogue prepared from moxifloxacin as raw material and preparation method and application thereof
US9605017B2 (en) 2′, 5′-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof
CN109761997B (en) Preparation and application of bis-fluoroquinolone thiadiazole urea N-methyl lomefloxacin derivative
CN113956233A (en) Amide compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant